Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Jennifer Chu
Findings point to faster way to find bacteria in food, water, and clinical samples
Matthew M. Lowe
Take this opportunity to prepare for the future
Etienne Nichols
QMSR for medical device companies
Kari Miller
CAPA systems require continuous management, effectiveness checks, and support
Etienne Nichols
The answers will reveal the truth about your product and get it to market faster

More Features

FDA Compliance News
Facilitates quick sanitary compliance and production changeover
Creates one of the most comprehensive regulatory SaaS platforms for the industry
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now

More News

The QA Pharm

FDA Compliance

FDA Demands Corporate Commitment at PolyCarbon Industries

Warning letter says bosses are responsible for QMS

Published: Tuesday, June 21, 2011 - 06:00

Just when you think that the Food and Drug Administration (FDA) has to stick to the script by quoting chapter and verse of current Good Manufacturing Practices (CGMPs), it gets very progressive and offers straight talk about corporate commitment and leadership.

I have reported before that the FDA expects corporate oversight of the quality management system. The Johnson & Johnson debacle is just one recent example where the FDA cited the corporate folks for taking their eyes off McNeil, where Tylenol is manufactured.

But the Warning Letter to PolyCarbon Industries recently posted on the FDA website has an added dimension—a call for commitment and leadership. The Warning Letter, dated Dec. 2, 2010, reads as follows:

“It is essential that your firm establish and maintain a corporate commitment to an effective pharmaceutical quality system. Your firm’s management should demonstrate leadership and ultimate responsibility by participating in the design, implementation, and monitoring for quality throughout the company. Management should establish policies that describe your firm’s overall approach to ensuring drug quality and communicate your expectation of compliance with all requirements of applicable federal law and FDA regulations.”

There’s a lot of insight packed into that paragraph. The most important aspect is what commitment and leadership behaviors look like from an FDA perspective.

So, let’s do a little behavioral analysis:

1. Does your corporate group participate in the design, implementation, and monitoring of quality at your company?

The best example of this that I have seen was a corporate group that facilitated a focused discussion of internal and external experts that led to the creation and deployment of company compliance policies.

The worst example was a company that hired a consultant to write the corporate policies. The policies appeared one day on the company intranet with the edict that they be deployed within six months. The old “right click on properties” revealed that the consultant had used the same policies for another client. The only thing different was the logo.

2. Does your corporate group establish and communicate policies regarding regulations and compliance requirements?

The best example of this that I have seen was a company that deployed the policies with the business message that compliance was important to patients and the ability to compete. Compliance was to be valued.

The worst example was a company that couched the compliance message in terms of FDA inspections getting tougher, and that—right or wrong—the bar was being raised. “We just have to face reality.”

Regulatory compliance is no different than any other area of the company that requires commitment and leadership. Frankly speaking, when there is little leadership in this area, I find little leadership in other areas, too.

So to our friends at the FDA, I say, “Spot on.”

Sometimes what needs to be said can’t be referenced to the Code of Federal Regulations but is truly at the heart of the problem.


About The Author

The QA Pharm’s picture

The QA Pharm

The QA Pharm is a service of John Snyder & Co. Inc., provider of consulting services to FDA-regulated companies to build quality management systems and develop corrective actions that address regulatory compliance observations and communication strategies to protect against enforcement action. John E. Snyder worked at the lab bench, on the management board, and as an observer of the pharmaceutical industry for more than 30 years. His posts on The QA Pharm blog are straight talk about the challenges faced by company management and internal quality professionals. Synder is the author of Murder for Diversion (Jacob Blake Pharma Mystery Series Book 1).